A genome-wide CRISPR screen identifies genes critical for resistance to FLT3 inhibitor AC220

Cancer Research

Volumn 77, Issue 16, 2017, Pages 4402-4413

  Hou, Panpan ^a,b   Wu, Chao ^b   Wang, Yuchen ^b,c   Qi, Rui ^b   Bhavanasi, Dheeraj ^d   Zuo, Zhixiang ^e   Dos Santos, Cedric ^f   Chen, Shuliang ^a   Chen, Yu ^a   Zheng, Hong ^g   Wang, Hong ^b   Perl, Alexander ^d   Guo, Deyin ^a   Huang, Jian ^b  

^a WUHAN UNIVERSITY   (China)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^f AMGEN INC   (United States)

^g PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; FIBROBLAST GROWTH FACTOR; GLYCOGEN SYNTHASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE; QUIZARTINIB; RAS PROTEIN; SPROUTY PROTEIN; SPRY3 PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN; BENZOTHIAZOLE DERIVATIVE; CARBANILAMIDE DERIVATIVE; FLT3 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ACUTE MYELOID LEUKEMIA; ANIMAL CELL; ARTICLE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CONTROLLED STUDY; DRUG RESPONSE; GENE; GENE EXPRESSION; GENETIC SCREENING; GSK3 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; LOSS OF FUNCTION MUTATION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPRY3 GENE; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; CHILD; DRUG RESISTANCE; GENETIC TRANSFECTION; GENETICS; LEUKEMIA, MYELOID, ACUTE; MALE; MUTATION; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; BENZOTHIAZOLES; CELL LINE, TUMOR; CELL PROLIFERATION; CHILD; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; DRUG RESISTANCE, NEOPLASM; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MUTATION; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 85028321894     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-1627     Document Type: Article

References (54)

1. Parcells BW, Ikeda AK, Simms-Waldrip T, Moore TB, Sakamoto KM. FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia. Stem Cells 2006;24:1174–84.
2. Naoe T, Kiyoi H. Normal and oncogenic FLT3. Cell Mol Life Sci 2004;61: 2932–8.
3. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100:1532–42.
4. Levis M, Small D. FLT3: ITDoes matter in leukemia. Leukemia 2003;17:1738–52.
5. Estey EH.Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol 2013;88:318–27.
6. Konig H, Levis M. Targeting FLT3 to treat leukemia. Expert Opin Ther Targets 2015;19:37–54.
7. Swords R, Freeman C, Giles F. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. Leukemia 2012;26:2176–85.
8. Perl AE, Carroll M. Exploiting signal transduction pathways in acute myelogenous leukemia. Curr Treat Options Oncol 2007;8:265–76.
9. Takahashi S.Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. J Hematol Oncol 2011;4:13.
10. Grafone T, Palmisano M, Nicci C, Storti S. An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment. Oncol Rev 2012;6:e8.
11. Gilliland DG.FLT3-activating mutations in acute promyelocytic leukae-mia: a rationale for risk-adapted therapy with FLT3 inhibitors. Best Pract Res Clin Haematol 2003;16:409–17.
12. Small D.Targeting FLT3 for the treatment of leukemia. Semin Hematol 2008;45:S17–21.
13. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003;3:650–65.
14. Fathi A, Levis M. FLT3 inhibitors: a story of the old and the new. Curr Opin Hematol 2011;18:71–6.
15. Scott E, Hexner E, Perl A, Carroll M. Targeted signal transduction therapies in myeloid malignancies. Curr Oncol Rep 2010;12:358–65.
16. Smith CC, Shah NP. The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. Am Soc Clin Oncol Educ Book 2013:313–8.
17. Wander SA, Levis MJ, Fathi AT. The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. Ther Adv Hematol 2014;5:65–77.
18. Guy GR, Jackson RA, Yusoff P, Chow SY. Sprouty proteins: modified modulators, matchmakers or missing links? J Endocrinol 2009;203:191–202.
19. Kim HJ, Bar-Sagi D. Modulation of signalling by Sprouty: a developing story. Nat Rev Mol Cell Biol 2004;5:441–50.
20. Edwin F, Anderson K, Ying C, Patel TB. Intermolecular interactions of Sprouty proteins and their implications in development and disease. Mol Pharmacol 2009;76:679–91.
21. Felfly H, Klein OD. Sprouty genes regulate proliferation and survival of human embryonic stem cells. Sci Rep 2013;3:2277.
22. Edwin F, Singh R, Endersby R, Baker SJ, Patel TB. The tumor suppressor PTEN is necessary for human Sprouty 2-mediated inhibition of cell proliferation. J Biol Chem 2006;281:4816–22.
23. Holgren C, Dougherty U, Edwin F, Cerasi D, Taylor I, Fichera A, et al. Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: sprouty/c-Met upregulation in human colonic adenocarcino-mas. Oncogene 2010;29:5241–53.
24. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003;116:1175–86.
25. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 2001;359:1–16.
26. Hedgepeth CM, Conrad LJ, Zhang J, Huang HC, Lee VM, Klein PS. Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev Biol 1997;185:82–91.
27. Shaffer BC, Gillet JP, Patel C, Baer MR, Bates SE, Gottesman MM. Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist Updat 2012;15:62–9.
28. Estey EH.Acute myeloid leukemia: 2014 update on risk-stratification and management. Am J Hematol 2014;89:1063–81.
29. Weisberg E, Choi HG, Barrett R, Zhou W, Zhang J, Ray A, et al. Discovery and characterization of novel mutant FLT3 kinase inhibitors. Mol Cancer Ther 2010;9:2468–77.
30. Sudhindra A, Smith CC. FLT3 inhibitors in AML: are we there yet? Curr Hematol Malig Rep 2014;9:174–85.
31. Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 2014;343:84–7.
32. Hou P, Chen S, Wang S, Yu X, Chen Y, Jiang M, et al. Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. Sci Rep 2015;5:15577.
33. Quentmeier H, Reinhardt J, Zaborski M, Drexler HG. FLT3 mutations in acute myeloid leukemia cell lines. Leukemia 2003;17:120–4.
34. Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 2010;116:5089–102.
35. Jiang J, Griffin JD. Wnt/beta-catenin pathway modulates the sensitivity of the mutant FLT3 receptor kinase inhibitors in a GSK-3beta dependent manner. Genes Cancer 2010;1:164–76.
36. Tickenbrock L, Schwable J, Wiedehage M, Steffen B, Sargin B, Choudhary C, et al. Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction. Blood 2005;105:3699–706.
37. Wright AV, Nunez JK, Doudna JA. Biology and Applications of CRISPR systems: harnessing nature's toolbox for genome engineering. Cell 2016; 164:29–44.
38. Sander JD, Joung JK. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol 2014;32:347–55.
39. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 2014;157:1262–78.
40. Marraffini LA.CRISPR-Cas immunity in prokaryotes. Nature 2015;526: 55–61.
41. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013;339:819–23.
42. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-guided human genome engineering via Cas9. Science 2013;339:823–6.
43. Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 2014;346:1258096.
44. Wang T, Birsoy K, Hughes NW, Krupczak KM, Post Y, Wei JJ, et al. Identification and characterization of essential genes in the human genome. Science 2015;350:1096–101.
45. Ma H, Dang Y, Wu Y, Jia G, Anaya E, Zhang J, et al. A CRISPR-based screen identifies genes essential for west-nile-virus-induced cell death. Cell Rep 2015;12:673–83.
46. Parnas O, Jovanovic M, Eisenhaure TM, Herbst RH, Dixit A, Ye CJ, et al. A genome-wide CRISPR screen in primary immune cells to dissect regulatory networks. Cell 2015;162:675–86.
47. Shi J, Wang E, Milazzo JP, Wang Z, Kinney JB, Vakoc CR. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat Biotechnol 2015;33:661–7.
48. Chen S, Sanjana NE, Zheng K, Shalem O, Lee K, Shi X, et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell 2015;160:1246–60.
49. Kiyoi H.Flt3 inhibitors: recent advances and problems for clinical application. Nagoya J Med Sci 2015;77:7–17.
50. Engen CB, Wergeland L, Skavland J, Gjertsen BT. Targeted therapy of FLT3 in treatment of AML-current status and future directions. J Clin Med 2014;3:1466–89.
51. Fathi AT, Chen YB. Treatment of FLT3-ITD acute myeloid leukemia. Am J Blood Res 2011;1:175–89.
52. Weisberg E, Barrett R, Liu Q, Stone R, Gray N, Griffin JD. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat 2009;12:81–9.
53. Williams AB, Nguyen B, Li L, Brown P, Levis M, Leahy D, et al. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013;27:48–55.
54. Traer E, Martinez J, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, et al. FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia. Cancer Res 2016;76:6471–82.